In vivo effects by estrone sulfate on the central nervous system-senile dementia (alzheimer's type)

https://doi.org/10.1016/0022-4731(89)90137-4Get rights and content

Abstract

Seven women with senile dementia-Alzheimer's type (SDAT) were treated with conjugated estrogen [main content: estrone sulfate (E1-S)], at a dose of 1.25 mg/day over a 6-week period. A New Screening Test for Dementia developed by Japanese National Institute of Mental Health (NS) and the scores of Hasegawa Scale for dementia (HS) were performed every 3 weeks. Six women showed improvements in NS (P < 0.05) and 5 women showed improvements in HS. Untreated women with SDAT did not show any improvement.

Serum E,-S was measured by a direct radioimmunoassay. Serum E1-S was 911 ± 156 pg/ml in 7 women with SDAT and lower than that of 7 normal women (1020 ± 216 pg/ml). Following the treatment, serum E1-S increased to a level of 21.1 ± 8.1 ng/ml. Estrone and estradiol-17β also increased. The results suggest a possibility for the future clinical use of estrogen for senile dementia, after careful clinical research trials including the side effects.

References (25)

  • B.W. Hackman et al.

    Replacement therapy with piperazine oestrone sulphate (‘Hormogen’) and its effect on memory

    Curr. Med. Res. Opin.

    (1976)
  • E.L. Klaiber et al.

    Estrogen therapy for severe persistent depressions in women

    Archs gen. Psychiat.

    (1979)
  • Cited by (217)

    • Alzheimer's disease: Review of hormone therapy trials and implications for treatment and prevention after menopause

      2014, Journal of Steroid Biochemistry and Molecular Biology
      Citation Excerpt :

      These observations suggest that starting estrogen-containing hormone therapy might improve Alzheimer symptoms. Indeed, small uncontrolled and nonrandomized studies raised early hope that initiating an estrogen or an estrogen plus a progestogen would benefit cognition in this disorder [42–44]. However, a potential causal relation between hormone therapy and cognitive symptoms of Alzheimer's disease is better addressed by clinical trials that examine this association directly.

    • Alzheimer's disease in women

      2009, Best Practice and Research: Clinical Obstetrics and Gynaecology
    View all citing articles on Scopus

    Proceedings of the 9th International Symposium of the Journal of Steroid Biochemistry, Recent Advances in Steroid Biochemistry, Las Palmas, Canary Islands, Spain, 28–31 May 1989.

    View full text